ABSTRACT
4-Sulfamoyl pyrroles were designed as novel hepatoselective HMG-CoA reductase inhibitors (statins) to reduce myalgia, a statin-induced adverse effect. The compounds were prepared via a [3+2] cycloaddition of a Münchnone with a sulfonamide-substituted alkyne. We identified compounds with greater selectivity for hepatocytes compared to L6-myocytes than rosuvastatin and atorvastatin. There was an inverse correlation of myocyte potencies and ClogP values. A number of analogs were effective at reducing cholesterol in acute and chronic in vivo models but they lacked sufficient chronic in vivo activity to warrant further development.
Subject(s)
Hydroxymethylglutaryl-CoA Reductase Inhibitors/chemical synthesis , Hydroxymethylglutaryl-CoA Reductase Inhibitors/pharmacology , Muscle Cells/drug effects , Pyrroles/chemical synthesis , Pyrroles/pharmacology , Sulfonamides/chemical synthesis , Sulfonamides/pharmacology , Animals , Atorvastatin , Combinatorial Chemistry Techniques , Disease Models, Animal , Fluorobenzenes/pharmacology , Hepatocytes/drug effects , Heptanoic Acids/pharmacology , Hydroxymethylglutaryl-CoA Reductase Inhibitors/chemistry , Mice , Molecular Structure , Pyrimidines/pharmacology , Pyrroles/chemistry , Rosuvastatin CalciumABSTRACT
Compounds of the general structure A and B were investigated for their activity as lipoprotein(a), [Lp(a)], assembly (coupling) inhibitors. SAR around the amino acid derivatives (structure A) gave compound 14-6 as a potent coupling inhibitor. Oral dosing of compound 14-6 to Lp(a) transgenic mice and cymologous monkeys resulted in a>30% decrease in plasma Lp(a) levels after 1-2 weeks of treatment at 100 mg/kg/day.
Subject(s)
Amino Acids/pharmacology , Lipoprotein(a)/antagonists & inhibitors , Sulfonamides/pharmacology , Amino Acids/chemistry , Animals , Cell Line , Dose-Response Relationship, Drug , Haplorhini , Humans , Inhibitory Concentration 50 , Lipoprotein(a)/biosynthesis , Lipoprotein(a)/blood , Mice , Mice, Transgenic , Structure-Activity Relationship , Sulfonamides/chemistryABSTRACT
Interleukin-8 modulation is implicated in many inflammatory and cancer diseases. Starting from a mass-screening hit, the synthesis and structure-activity relationship of 2-amino-3-heteroarylquinoxalines as non-peptide, small molecule interleukine-8 receptor antagonists have been developed. The optimized derivatives, PD 0210293 (13y) and PD 0220245 (13r), show inhibition of both IL-8 receptor binding and IL-8-mediated neutrophil chemotaxis.
Subject(s)
Quinoxalines , Receptors, Interleukin-8A/antagonists & inhibitors , Anti-Inflammatory Agents/chemistry , Antineoplastic Agents/chemistry , Calcium/metabolism , Chemotaxis/drug effects , Diamines/chemical synthesis , Diamines/chemistry , Diamines/pharmacology , Humans , Quinoxalines/chemical synthesis , Quinoxalines/chemistry , Quinoxalines/pharmacology , Receptors, Interleukin-8A/metabolism , Structure-Activity RelationshipABSTRACT
The search for potent and efficacious inhibitors of the enzyme HMG-CoA reductase (HMGRI) was the focus of considerable research in the 1980s. Building on the discovery of the fungal metabolite-derived inhibitors, mevastatin, lovastatin, pravastatin and simvastatin, a number of totally synthetic inhibitors were discovered and developed. This manuscript describes the discovery and development of one of those synthetic inhibitors, atovastatin calcium, currently marketed in the United States as LIPITOR. This inhibitor was designed based in part on molecular modeling comparisons of the structures of the fungal metabolites and other synthetically derived inhibitors. In addition to development of the structure-activity relationships which led to atorvastatin calcium, another critical aspect of the development of this area was the parallel improvement in the chemistry required to prepare compounds of the increased synthetic complexity needed to potently inhibit this enzyme. Ultimately, the development of several chiral syntheses of enantiomerically pure atorvastatin calcium was accomplished through a collaborative effort between discovery and development. The impact of the progress of the required chemistry as well as external factors on internal decision-making with regards to the development of atorvastatin calcium will be discussed.
